of sympathomimetic drugs is reviewed by Runciman 4 in this issue of Anaesthesia and Intensive Care and one point is of particular relevance to this discussion, If sympathetic activity increases, by whatever mechanisms, in the presence of a beta-blocker, the alphaadrenergic component will predominate. A reduction in cardiac output may result as peripheral vascular resistance increases without any accompanying increase in myocardial contractility.
Although beta-adrenergic blockers have been widely used for 20 years, their potential risk during anaesthesia is still controversial. As they are very potent and specific it is important to know their pharmacological actions, interactions, and the physiological consequences of these.
The belief that a normally functioning sympathetic nervous system is essential to the maintenance of life and health is challenged because it has been shown that the sympathetic nervous system's response to such stresses as anxiety, pain, noxious stimuli or endocrine disease states is not necessarily beneficial or harmless but may lead to morbidity or even death.
Anaesthetists continually use drugs which have specific actions on critical bodily functions. A knowledge of the pharmacology of these drugs allows us to utilise their desirable Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 qualities, recognise and treat their unwanted secondary effects and antagonise their primary effects if the occasion demands. For example, no unavoidable hazard accompanies the use of a neuromuscular blocking drug although voluntary muscle activity is abolished or diminished. But there is continuing concern regarding the safety of beta-blockers during anaesthesia, although their pharmacology has been precisely defined in thousands of publications, including detailed advice on their rational use perioperatively.
This review presents an outline of the pharmacology of beta-adrenergic blockade and the physiological consequences in the surgical patient. An attempt is made to present to the anaesthetist a rational approach to betablockade based on a selection of the available experimental and clinical evidence. BACKGROUND The present classification of adrenergic receptors was laid down by Ahlquist in 1948. 5 As the result of a study of the cardiovascular effects of five sympathomimetic amines and the effect on their action of dibenamine, the only specific adrenergic blocking agent then available, 6 Ahlquist divided adrenergic receptors into two functional groups, alpha and beta. Functions which responded most strongly to noradrenaline and whose responses were suppressed by dibenamine were said to be mediated through alpha-adrenergic receptors. Beta-receptors were stimulated maximally by isoprenaline and were little influenced by dibenamine. Other sympathomimetic agents produced a varying mixture of alpha and beta stimulation.
These proposals were vindicated ten years later by the development of the first specific beta-blocker, dichloroisoprenaline (DCIf which fulfilled the criteria necessary for a specific beta-adrenergic blocking drug, i.e. an agent which specifically and competitively blocks the action of isoprenaline on betareceptors in a dose dependent agonistantagonist relationship. Other tissue responses remain unimpaired, e.g., the positive cardiac inotropic action of calcium or digitalis glycosides is not influenced by the presence of the agent. Drugs such as general anaesthetic agents which depress many aspects of cellular function reduce the effects of all positive Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 inotropic agents equally and must not be regarded as specific beta-blockers. 8 DCI had no clinical application as it exhibited potent intrinsic sympathomimetic activity (ISA). This property, seen to a lesser extent in some of the presently available betablockers, implies that the drug itself has a beta stimulating effect in addition to competitively blocking the response to the beta-agonist, isoprenaline. DCI was useful in defining the functional characteristics of beta adrenocreceptors, and it stimulated the search for the currently used beta-blockers.
The elaboration of new compounds and alterations of their chemical structure resulted in the identification of many sub-groups of beta-adrenoreceptors. Differentiation into beta 1 (cardiac) and beta-2 (bronchial and peripheral) receptors as proposed by Lands et al. 9 is no longer strictly accurate. Vaughan Williams IO considered that the potential number of sub-groups is so large that reference to betaadrenoreceptors should be made "in terms of the animal, the tissue, and the responses which they mediate, e.g. human chronotropic cardiac adrenoreceptors". While this view may be theoretically precise, Ahlquist ll considered that for all practical purposes the division of betareceptors into types 1 and 2 is adequate to meet the needs of the clinician in his understanding and choice of beta-blocking drugs. This view applies especially in relation to anaesthesia. It must be stressed that the terms "cardioselective" or "beta-l selective" refer only to a relative specificity for cardiac betareceptors because such drugs have some effect on beta-2 receptors. This relative specificity is dose related, tending to be lost at high dose levels. "Non-selective" beta-blockers act on both groups of beta-receptors at all dose levels.
Some clinically used beta-blockers exhibit a degree of ISA. It has been argued that such activity may make a particular drug more suitable than another for particular applications, e.g. in patients with reversible airways obstruction or in those whose preexisting cardiac failure has been controlled with digitalis and/or diuretics. It is difficult to see how this property confers any definite therapeutic advantage if the object of therapy is to reduce the physiological effects of betaadrenergic stimulation.
Beta-blockers may also exhibit membrane stabilising activity often referred to as the "quinidine-like effect" (Class I cardiac muscle membrane activityI°); but the anti-arrhythmic effects of these drugs has been shown to be due to beta-blockade and is unrelated to their membrane stabilising effect. 12 Propranolol is a local anaesthetic equipotent to lignocaine 13 and exhibits significant Class 1 activity but does not have ISA. Oxprenolol and alprenolol display both the quinidine-like effect and ISA while practolol (now only available for parenteral use) has only mild rSA. Sotalol is devoid of either property. The properties of available beta-blockers are summarised in Table 1 .
Structure-activity relationships
Beta-blockers bear some structural similarities to isoprenaline. Most compounds contain a substituted benzene ring to which is attached an alkyl-amino side chain. In general, the affinity for beta receptors increases with the length of the alkyl group and branched alkyl groups confer greater potency. Hydroxyl substitution on the beta carbon atom results in optical isomerism. As with sympathomimetic amines the laevorotatory isomers show much more receptor activity than the dextrorotatory forms. Commercial preparations contain racemic mixtures of the isomers.
Absorption and bioavailability
Absorption of orally administered beta-blockers is virtually complete except for atenolol which is variable. Peak blood levels occur one to three hours after administration. Bioavailability is variable (Tables 2 and 3) . Orally administered propranolol, alprenolol and oxprenolol are extensively metabolised by the liver. This "first pass" effect results in much of the drug being metabolised before it can reach the systemic circulation. The extent of this effect is dose-dependent, the larger the dose the larger the proportion which reaches the systemic circulation. Pindolol and practolol are little influenced by this effect. The "first pass" effect must be considered when an equivalent intravenous dose needs to be calculated for a patient unable to continue oral therapy especially in the postoperative period. Other factors such as protein binding and lipid solubility alter the pharmacokinetic and pharmacodynamic properties of the various beta-blockers but their detailed consideration is beyond the scope of this review.
Several authors have observed that the duration of beta-blockade is considerably longer than would be indicated by the elimination half-lives of the drugs. Plasma concentration and clinical effect may therefore not be directly associated. For this reason, many agents are now administered twice daily. An excellent review has recently been presented by Frishman. 12 The duration of effective betablockade after surgery is related to drug dosage and the time of administration of the last dose. ;!:zzzzz;!: I I Prys-Roberts l4 found that a very significant degree of beta-blockade was still present 48 hours after surgery in a group of renal hypertensive patients who had been receiving propranolol, oxprenolol or labetolol in large doses (equivalent to propranolol 10 to 36 mg/kg/day) up to four hours pre-operatively. It should be noted that the doses needed to control refactory hypertension are often far bigger than those used for angina pectoris. The mode of action is partly related to betablockade, partly to reduction of plasma renin levels and/or an effect on the blood pressure control mechanisms in the brain stem.
TABLE 1

Pharmacological propenies SOllle differences belween bela-adrenoreceplor blocking drugs
--------_ . _ ---- Beta-blockade
THE SYMPATHETIC NERVOUS SYSTEM AND CARDIOVASCULAR HOMEOSTASIS The Sympathetic Response to Stress in the A wake Subject
The role of the sympathetic nervous system (SNS) in raising the state of physiological responsiveness when animals are threatened, stressed, or injured has been extensively investigated. Enhanced sympathetic nervous and humoral activity are the basis of the integrated response to stress which was described by Canon. IS The term "fright, flight or fight reaction" is inaccurate as it implies that the response occurs only in the conscious animal. Unconsciousness does not, however, necessarily prevent a response by the sympathetic nervous system to physical stresses such as haemorrhage, hypoxia or surgical stimuli.
The sympathetic response to stress, acting on appropriate effector sites, results in a temporary improvement of those body functions most necessary to the preservation of life by a partial functional shut-down of "nonessential" organ systems. But a price is paid for this heightened reactivity; body energy stores become rapidly depleted and those functions which have been slowed down or stopped must at some stage be resumed for long term survival. The determinants of the eventual outcome are the nature, intensity and duration of the stress and the innate fitness (state of general health) of the animal. The evoked responses may become harmful if the stress is prolonged or if pathological changes render particular organs unable to respond without sustaining injury in their attempt to do so. In general, beta-adrenergic receptor stimulation increases the rate and force of cardiac contraction increasing the cardiac output. The resistance vessels in skeletal muscle dilate while simultaneous alpha receptor stimulation reduces blood flow in the cutaneous and splanchnic beds by vasoconstriction. Blood flow is therefore preferent~lly distributed to brain, voluntary muscles, and heart. At very high levels of sympathetic activity alphamediated vasoconstriction predominates in striated muscle. Smooth muscle in the walls of hollow viscera relaxes while sphincteric muscle contracts interrupting motility and function. Relaxation of tracheo-bronchial muscle increases bronchial calibre and decreases airway resistance. The metabolic effects of stimulation of the SNS include the release of additional insulin from the pancreas, 16 an increased production of glucose from glycogenolysis in muscle and lipolysis. Alpha adrenergic stimulation facilitates hepatic glycogenolysis. 17 In summary, the most important cardiovascular adaptations to stress are mediated through the beta-receptors of the SNS while alpha-receptor stimulation plays a complementary role by reducing blood flow in tissues which are not vital to short term survival.
The Response to Stress under Anaesthesia
Much less is known about the homeostatic role of the SNS during general anaesthesia than in the conscious state. The psychic element is absent but physical stress may occur. The Inhalational anaesthetic agents affect the SNS in different ways. Recording from SNS nerve fibres has been used as an index of activity, but direct effects of an anaesthetic agent on an end-organ may modify the response to SNS activity. In addition, changes in the levels of circulating catecholamines induced by an anaesthetic agent may modify the neurally mediated SNS response to that agent. Many studies have described varying levels of activity of the cardiovascular system with various inspired concentrations of anaesthetic agents. The activity of the cardiovascular system under anaesthesia has been used as an index of SNS activity, but direct effects of the agent itself on the cardiovascular system may again modify the responses to changes in SNS activity. The interaction of all these factors must be taken into account when the response to stress during anaesthesia and operation is being considered.
THE EFFECTS OF ANAESTHETIC AGENTS ON SYMPATHETIC FUNCTION
Central Sympathetic Effects
Direct recording from sympathetic nerves has demonstrated that many anaesthetic agents increase impulse traffic in the pre-ganglionic cardiac sympathetic nerves of experimental animals. Biscoe and Millar '8 showed that cyclopropane, halothane, and diethyl ether all resulted in increased pre-ganglionic sympathetic activity in the cat. Price et al. 19 demonstrated an increase in central sympathetic outflow during cyclopropane anaesthesia, while Skovsted and Price 20 ,21 found increased sympathetic neural activity to occur during the administration of fluroxene and diethyl ether. They considered a depression of medullary sympathetic depressor neurones to be the most likely mechanism.
Actions on Sympathetic Ganglia
Sympathetic ganglionic blockade was demonstrated in the stellate ganglion by Biscoe and Millar 's in cats anaesthetised with halothane. Integrated spontaneous postganglionic sympathetic activity was unchanged in some fibres and reduced in others during halothane anaesthesia in rabbits 'S but cyclopropane and ether both resulted in increased post-ganglionic discharge. Garfield and colleagues 22 studied spinal dogs using heart rate changes as a measure of ganglionic transmission, and found that diethyl ether or halothane gave partial ganglionic block, while 70OJo nitrous oxide or cyclopropane up to 20% concentration had little effect. It is still not clear whether sympathetic ganglionic effects are of any practical significance.
Effects on Circulating Catecholamines
Major elevations of plasma adrenaline and noradrenaline levels are associated with the administration of diethyl ether 23 and cyclopropane. 24 The addition of nitrous oxide to halothane anaesthesia in humans has been shown to elevate plasma noradrenaline levels. 25 Trichlorethylene does not affect blood catecholamine levels 26 but more recent studies show that it increases the degree of cardiac beta stimulationY Halothane,26 enflurane 28 and methoxyflurane 29 do not cause any increase in catecholamine output. The evidence concerning isoflurane is conflicting but suggests that only slight sympatho-adrenal stimulation occurS. 30 ,31 Bristow et al. 32 found that nitrous oxide and halothane anaesthesia severely depressed the baroreflex, obtunding the usual tachycardic and pressor responses to low arterial blood pressure. They concluded that this was responsible for the low levels of arterial blood Anaesthesia and Inlensive Care, Vol. VI/I, No. 3, August. 1980 pressure often observed during this form of anaesthesia.
The support which the cardiovascular system may receive from neural or humoral mechanisms during anaesthesia is of great importance. All clinically used anaesthetic agents are, to a lesser or greater degree, direct depressants of the contractile state of the myocardium. This may be counteracted to some extent by adrenergic myocardial stimulation (neurally or humorally mediated) during anaesthesia with certain agents, most notably cyclopropane and diethyl ether. Loss of adrenergic support by cardiac beta-receptor blockade might be expected to unmask their direct myocardial depressant properties, as reported by Craythorne and Huffington 33 and J orfeldt et al. 34 Increased myocardial contractility and cardiac output during moderate hypercapnia under anaesthesia has been shown to be the result of a similar mechanism 35 and is also abolished by betablockade. Similarly, the hyperkinetic high cardiac output state associated with normovolaemic anaemia is largely due to increased sympathetic activity and serious impairment of oxygen transport to the tissues occurs if beta-blockers are administered. 36 Strong et al. 37 have warned against the intraoperative use of beta-blockers unless hypercapnia, metabolic acidosis or hypovolaemia can be confidently excluded.
THE DEPTH OF ANAESTHESIA
It has long been known that if anaesthesia becomes too deep death may result from respiratory or cardiac "paralysis" . 38 Anaesthetists therefore began to use inhalational anaesthesia at the lightest level compatible with good operating conditions; an approach which has continued up to the present. In particular muscle relaxants provided a means by which a patient could be kept in a plane of anaesthesia just sufficient to maintain unconsciousness while providing perfect operating conditions. During light anaesthesia plus muscle relaxants stimuli such as surgical intervention cannot evoke a response from voluntary muscles but produce the usual response of the autonomic nervous system to stress. These responses, which are mainly sympathetic, are tolerated by most normal patients, but may prove extremely harmful to patients with cardiovascular disease. The avoidance of the dangers of deep anaesthesia may thus create other dangers. Hence a further criterion of safe anaesthesia is the avoidance of undesirable autonomic reflex activity. 39 The effects of surgical stimulation during light anaesthesia are frequently observed. Apart from skeletal muscular responses, sympathetic activity causes a tachycardia and an increase in arterial blood pressure which may result in increased blood loss, myocardial ischaemia or cardiac dysrhythmias. Despite the early records of deaths during chloroform anaesthesia the effect of reflex sympathetic activity on the heart has been largely neglected. The demonstration of very high levels of sympathetic discharge during chloroform anaesthesia 40 and the tendency of this agent to increase ventricular "irritability" now provides a logical explanation for the deaths in ventricular fibrillation of healthy but anxious, lightly anaesthetised patients.
Continuous monitoring of the ECG under anaesthesia has revealed that undesirable disturbances of cardiac rhythm are common. Most of these observations were made during anaesthesia in the dental chair. The patient is usually fit and may be unpremedicated while the surgical stimulus is intense. A high incidence of ventricular dysrhythmias, including multi focal extrasystoles and episodes of ventricular tachycardia, has been observed. 41 ,42,43 Although these dysrhythmias appeared to be tolerated by fit patients and subsided when the painful stimulus ceased, they were considered to be hazardous. Similar dysrhythmias were observed by Jenkins 44 during diagnostic bronchoscopy. All these authors reported that premedication with a small oral dose of a beta-blocker or their administration intravenously during the procedure greatly reduced the incidence of dysrhythmias or prevented them completely.
Patients with cardiovascular disease are more susceptible to the deleterious effects of greatly increased sympathetic activity and appear to be in a more precarious situation. Prys-Roberts et al. 45 clearly demonstrated undesirable electrocardiographic (ECG) and blood pressure changes in untreated hypertensive patients during laryngoscopy and endotracheal intubation under anaesthesia. Large elevations of arterial blood pressure were often accompanied by sinus tachycardia with multi focal ventricular ectopic beats. ST segment depression and T wave inversion in the ECG were common and indicated myocardial ischaemia. The authors inferred that increases in myocardial oxygen consumption (MV0 2 ) had occurred, mainly due to increases both in heart rate and impedance to left ventricular ejection. 46 Similar ECG changes have been observed in conscious patients with coronary artery disease during psychological stress 47 and may be accompanied by anginal pain. Psychological stress or a hypersensitivity to adrenergic stimulation 48 may be implicated in the increased incidence of myocardial infarction or ischaemic episodes if beta-blockers are suspended during the period preceding coronary artery surgery for ischaemic heart disease. 49 ,5o This view is contrary to that of Viljoen, Estafanous and Kellner 51 (see below under "methoxyflurane") who used methoxyflurane anaesthesia. Methoxyflurane has since been shown to seriously impair myocardial function in the presence of beta-blockers. 52 Kopriva, Brown and Pappas 53 found, in a prospective study of a similar group of patients undergoing coronary artery bypass surgery, that haemodynamic function intra-and post-operatively was similar whether the patients were treated with betablockers up to the time of operation (average propranolol dose 140 mg/day) or untreated. The anaesthesia employed was nitrous oxide/oxygen and halothane (up to 2070) with IPPV. They concluded that patients taking beta-blockers could be maintained on this therapy without increasing anaesthetic risk. This result is compatible with the findings of Prys-Roberts et al. 54 (using a similar anaesthetic technique) that in dogs with induced myocardial infarction, propranolol 0.3 mg/kg intravenously did not significantly impair cardiovascular function.
The function of the sympathetic nervous system, while well understood in relation to the awake state, has still not been fully defined in the anaesthetised patient. Under certain forms of anaesthesia unimpaired sympathetic reactivity is essential to the maintenance of an adequate circulation. Under light anaesthesia in certain groups of patients unrestrained sympathetic responses may constitute a danger to the health or even the life of the patient. Each patient must be carefully assessed preoperatively before deciding whether pharmacological blockade of any of the effects of sympathetic stimulation would be beneficial, harmful, or simply meddlesome. The most serious potential risks are the precipitation of heart block or left ventricular failure in patients who require high levels of cardiac sympathetic "tone" to maintain atrio-ventricular conduction or left ventricular function. An exacerbation of airway obstruction may occur in asthmatic patients even if a beta-I ("cardioselective") drug such as metoprolol is used.
The Effects of Beta-Blockers on the Cardiovascular System
Reported studies of the influence of betablockers on various aspects of cardiovascular function may be divided into three main groups:
(1) Isolated heart and cardiac muscle experiments. (2) Animal experiments both in the awake and anaesthetised states. (3) Studies in awake or anaesthetised human subjects.
Isolated Heart and Cardiac Muscle
Experiments Nayler and Chang 55 conducted studies on isometrically contracting dog trabecular muscle, either from normal dogs, or those whose hearts had been depleted of noradrenaline by pretreatment with reserpine. Peak isometric tension was measured in the presence of concentrations of up to 1.0 mg/l of propranolol, oxprenolol and practolol. In this dose range propranolol exerted a significant negative inotropic effect whereas practolol had no effect and oxprenolol had a slightly positive effect. No difference was observed between the responses observed in normal and catecholamine depleted preparations. In further studies the concentrations of the three beta-blockers was increased to 3.6 mg/l and their effects on dog and human trabecular muscle were compared. Propranolol continued to have a dose-dependent negative inotropic effect as its concentration was increased, the maximum depression of peak developed isometric tension being -30070. Oxprenolol or practolol began to exert a negative inotropic effect, only at concentrations above 1.0 mg/l and the maximum depression of con tractility observed was 10070 to 15070. The responses of canine and human cardiac muscle to all drugs were qualitatively and quantitatively similar. Meier 56 using a cat papillary muscle preparation, found that propranolol in high concentration exerted a negative inotropic effect while oxprenolol had little influence on peak developed tension.
The mechanism by which propranolol exerts its negative inotropic effect in high concentrations has not been fully established. Radioactive calcium binding and exchange in the ultracentrifuged microsomal fraction of cardiac cells is impaired by propranolol. Adenosine triphosphatase activity is also reduced by the drug. 57 • 55 These may represent possible mechanisms for the negative inotropic effects of beta antagonists, but the concentrations required were far in excess of those which produced depression of contractility in isolated whole muscle experiments.
Lanthanum ions (La + +), which do not penetrate into the myoplasm have been used to displace calcium ions (Ca + +) from superficially located membrane storage sites. 58 The amount of Ca + + removed from isolated segments of canine trabecular muscle in this way was significantly reduced by levels of propranolol which decreased the peak tension developed during isometric contraction. As the storage sites referred to above have been shown to release calcium during the excitationcontraction sequence in cardiac muscle, interference with their function may be responsible for the observed depressant effect of propranolol. Practolol has a similar but lesser effect. Experiments in which the cell membrane was rendered freely permeable to calcium ions by soaking the muscle in chelating agent (EDT A) before immersing it in fluid containing varying concentrations of calcium (contracture solution) confirmed these observations. Tension in the muscle developed in proportion to the calcium concentration in the bath fluid. 55 The addition of propranolol did not have any negative inotropic effect under these conditions, and in fact a small positive inotropic effect was observed. This was considered to be due to an inhibition of uptake of calcium into the sarcoplasmic reticulum by propranolol thus leaving more calcium ions free to react with the contractile elements. These observations provide a rational basis to the observed effectiveness of ionised calcium as a positive inotropic agent in beta-blocked patients.
ANIMAL AND HUMAN STUDIES
Introduction
Any measurement relating to the state of the cardiovascular system includes a component which results from the state of sympathetic activity present at the time of measurement. If an existing high level of sympathetic activity is red uced, an "indirect depression" of cardiovascular function may result. Direct depression of the myocardium may only be said to have occurred when there has been a reduction of the functional capacity of the sarcomere totally independent of the effects of withdrawal of sympathetic activity.
The observed haemodynamic effects of beta adrenergic blockade are subject to variations depending on a number of factors: (a) The existing level of sympathetic activity.
This may vary greatly. The subject may be awake, asleep or anaesthetised. If awake, the levels of emotional and physical activity influence sympathetic activity. 59 During anaesthesia many factors may inter-react. Some anaesthetic agents cause direct sympathoadrenal stimulation while others reduce sympathetic activity. The depth of anaesthesia and the intensity of painful stimuli must also be considered. After beta-blockade the activity of the vagus is relatively unopposed by sympathetic action and may result in the production of varying degrees of decrease in heart rate. On the basis of these considerations, great caution must be exercised when comparing the haemodynamic effects of beta-blockade on subjects with different diseases or under differing conditions. Results published by workers who have employed different methods of study may also not be strictly comparable.
Animal Experiments in the A wake and
Anaesthetised States The effects of beta-blockade induced during different forms of anaesthesia have been widely studied in the dog. Gander et al. 60 administered propranolol 0.5 mg/kg intravenously to dogs anaesthetised with intravenous chloralose. Cardiac output fell by 35% and this change was accompanied by a decrease in heart rate and of the maximum rate of rise of left ventricular pressure (LV dP / dt max), while there was an increase in left ventricular end-diastolic volume (L VEDV). Similar results were observed by Nakano and Takashi 61 when propranolol 0.25 mg/kg intravenously was given to dogs after thoracotomy during pentobarbitone anaesthesia. In this study, right ventricular contractile force was measured by means of a Walton-Brodie strain gauge arch sutured to the surface of the right ventricle. Myocardial contractile force, cardiac output and stroke work fell after propranolol, left ventricular end-diastolic pressure (L VEDP) increased and mean arterial pressure (MAP) was maintained. Left ventricular function curves were shifted to the right. Craythorne and Huffington 33 found that cardiac output did not fall after propranolol 0.2 mg/kg intravenously in open chest dogs during 1070 halothane anaesthesia. During 20070 cyclopropane anaesthesia, betablockade resulted in large reductions of cardiac output from high levels to values similar to those observed during halothane anaesthesia in the same animals. This finding confirmed that high levels of sympathetic neural and humoral activity accompany cycloproprane anaesthesia and that this activity can be reduced by betablockade. It does not, however, necessarily support the authors' conclusion that betablockade was severely "cardiodepressant" in AnaeSlhesia alld Inlensi\'c Care, Vol. ~ ni, ,vo. 3, August, /980 these circumstances. Harry et al. 62 studied the effect of propranolol on the canine heart and concluded that in doses of 1 and 2 mg/kg, propranolol acted only as a beta-blocker and did not cause direct myocardial depression.
The observed effects of beta-blockade in association with anaesthesia may be influenced not only by the interaction of drug effects but also by other uncontrolled variables. An example of this is the study of Rouse 63 in dogs. Propranolol 0.5 mg/kg was administered intravenously to dogs immediately before induction of anaesthesia with intravenous thiopentone followed by deep ether anaesthesia with spontaneous ventilation. Eight out of the 11 beta-blocked animals died after gut manipulation designed to produce "surgical shock", while all untreated control dogs survived. When intermittent positive pressure ventilation (lPPV) was substituted for spontaneous ventilation another group of beta blocked animals survived the same procedure. Blood-gas or acid-base measurements were not performed during the studies. No conclusion could therefore be drawn as to the cause of the observed differences, although it is possible or even probable that hypoxia or hypercapnia due to respiratory depression may have been responsible for the deaths in the spontaneously breathing beta blocked group as they would have been depending on a high level of evoked sympathetic stimulation to maintain an adequate circulation.
Merlin and Tonnesen 64 anaesthetised closed chest dogs with 0.7% halothane and IPPV. Propranolol 0.25 mg/kg intravenously resulted in reductions in cardiac output and left ventricular stroke work. Mean arterial blood pressure (MAP), systemic vascular resistance (SVR) and LVEDP all increased. Similar large elevations of SVR accompanying reductions in cardiac output due to propranolol were observed by Weis and Brackebusch 65 in open chest dogs anaesthetised with 1.50/0 halothane/nitrous oxide/oxygen. MAP was therefore maintained and the authors felt that MAP was an inadequate guide to that state of the circulation in these circumstances.
The haemodynamic effects of intravenous practolol in dogs during 0.9% halothane anaesthesia with IPPV were studied by Merin. 66 During steady state anaesthesia a dose of 0.65
Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 mg/kg was given, followed 20 minutes later by a further dose of the same magnitude. There was no evidence of depression of ventricular function; left ventricular stroke work and LV dP/dt max increased while cardiac filling pressures remained unchanged. Cardiac output did not alter after either dose. Significant elevations of heart rate, SVR and mean arterial pressure were observed. The results of this carefully controlled study contrast sharply with those of Strong et al. 67 ,37 These investigators found that practolol 1.2 mg/kg depressed left ventricular function in dogs during 1.0% halothane/nitrous oxide/oxygen anaesthesia with spontaneous respiration. Heart rate and cardiac output were both reduced after practolol was given. Control values for heart rate (192 in one animal) and L VEDP values (up to 45 mmHg) suggested that the spontaneously breathing animals were likely to be suffering from CO 2 retention before practolol was administered. Blood gas measurements were not, however, performed.
Oxprenolol, administered in incremental intravenous doses up to a total of 1.6 mg/kg during nitrous oxide/oxygen/0.5% halothane anaesthesia with IPPV and normocapnia, resulted in dose related increases in myocardial contractility, heart rate and cardiac output. No aspect of cardiovascular function was depressed even in the presence of a degree of beta-blockade sufficient to produce a 30-fold reduction in the chronotropic and inotropic responses to isoprenaline. This observation indicates that intravenous oxprenolol in much smaller doses than those referred to above should be a safe agent for use in acute situations especially where rapid reduction of sympathetic activity is required in a patient with hypertension or ischaemic heart disease. 68 
Interactions Between Beta-Blockers and Inhalational Anaesthetic Agents
All inhalational anaesthetic agents, including nitrous oxide, directly depress myocardial con tractility in a concentration dependent fashion. This direct effect may be modified if the anaesthetic agent enhances sympathetic activity on the heart or if its mode of administration leads to an increase in arterial Pc0 2 • Conversely if the anaesthetic causes a reduction in overall sympathetic activity this action will be additive to the direct myocardial depressant effect. Should the heart be functioning adequately only because of a preexisting high level of sympathetic "support", as in incipient or overt cardiac failure, withdrawal of this support can result in acute myocardial failure. Similarly, in the presence of major disorders of atrioventricular conduction (heart block), beta-blockers, by impairing the facilitatory effect of beta-stimulation on cardiac conducting tissue, may induce complete heart block.
For practical and ethical reasons, it has not been possible to perform stringently controlled "within patient" studies of the responses to anaesthesia, surgery, or potential hazards such as severe haemorrhage in human subjects before and after the institution of beta-blocker therapy or with or without the preoperative withdrawal of long-term therapy with betaadrenergic blocking drugs. Several good controlled studies have been performed in experimental animals, mainly dogs, and their results appear to confirm isolated clinical observations in man and the results of human studies performed within the limits of ethical considerations.
Studies have been performed using stable canine preparations in which the animals have been anaesthetised only with clinically relevant types of anaesthesia and subjected to stresses such as acute hypoxia, hypercapnia, haemorrhagic hypovolaemia or increasing depth of anaesthesia such as might occur in the anaesthetised human. The following is a summary of the results of some of these studies.
Halothane: Under conditions of normocapnia and IPPV, dogs pretreated with propranolol 20 mg/kg/ day for three weeks and an untreated control group tolerated increasing depths of halothane (up to 2.5 OJo inspired) anaesthesia well. There was a dose related degree of cardiovascular depression as halothane anaesthesia was deepened in the control group and this progressive depression was only slightly and predictably influenced by the presence of a very high degree of propranolol-induced beta-adrenergic blockade (demonstrated by a thirty-fold shift in the isoprenaline dose-response curve). The additional depression of cardiovascular function observed was predictable and equivalent to the effect of an additional 0.5OJo inspired halothane in untreated dogs at any given inspired concentration. 69 Transient severe hypoxia down to arterial oxygen tensions of 20-30 mmHg was tolerated equally well in both untreated and propranolol pretreated dogs (20 mg/kg/day for two weeks) at all depths of halothane anaesthesia (range IOJo to 2.5 OJo). 70 It is notable that neither treated or untreated animals responded with an increase in heart rate but that cardiac output was elevated by a rise in myocardial contractility and stroke volume. A similar response was observed during halothane anaesthesia in oxprenolol pretreated animals. 71 Coronary blood flow increased four to five fold in all groups. Coronary flow and Haldane effect related changes in myocardial pH are believed responsible for the increased contractility observed. 72 Graded haemorrhagic hypovolaemia up to 25OJo of estimated blood volume was equally well tolerated in propranolol or oxprenolol pretreated and control dogs under IOJo halothane anaesthesia and both groups returned to control haemodynamic values after reinfusion of the shed blood. A notable lack of effect on pulse rate was observed in both groups, supporting the view that pulse rate changes are of little use in the diagnosis of hypovolaemia during anaesthesia.
Trichlorethylene: Although this agent appears to be on the verge of historical interest only, the major manufacturer having ceased production as a result of potential carcinogenicity and minimal demand, it has been studied under similar conditions to those referred to above in relation to halothane. Trichlorethylene has not been reported to evoke a sympathetic response 26 as determined by blood catecholamine levels but it appears to have some sympathetic cardiac stimulant properties. It has been shown that the combination of trichlorethylene and propranolol or oxprenolol severely impairs the cardiovascular response to haemorrhagic hypovolaemia 27 ,71 and may result in irreversible shock even though blood volume is rapidly restored.
Enflurane: Horan et al. 73 demonstrated that propranolol in a dose proven not to cause direct myocardial depression 62 during steady-state enflurane anaesthesia at minimum effective anaesthetic concentration. The response to haemorrhage was markedly impaired and was noted to be significantly worse than that observed during halothane, trichlorethylene, methoxyflurane or isoflurane anaesthesia 31 in normal animals or in dogs with induced myocardial infarction under halothane/nitrous oxide anaesthesia with IPPV. 54 Methoxyflurane, although not known to rely on adrenergic stimulation to moderate its direct myocardial depressant effect,29 has been shown to be incompatible with beta-blockade in a canine modeP2 especially with hypovolaemia. This incompatibility, for which there is yet no explanation, may have been a significant factor in the published advice of Viljoen, Estefanous and Kelner 51 that patients undergoing coronary revascularisation surgery have beta-blocker therapy withdrawn two weeks before surgery because of an observed operative and postoperative mortality in patients maintained on beta-blocker therapy up to the time of surgery. These patients were anaesthetised with methoxyflurane.
Isoflurane has been thought not to significantly increase sympatho-adrenal activity,74,75 although studies employing more sensitive indices of beta-adrenergic cardiac stimulation such as max LVdP/dt and dQ/dt suggest that this agent may cause some degree of adrenergic stimulation. 31 Despite this apparent degree of sympathetic cardiovascular support during isoflurane anaesthesia, cardiac function was well maintained in the presence of beta-blockade with propranolol. Induced haemorrhage was far better tolerated than during trichlorethylene, methoxyflurane or enflurane anaesthesia.
Studies in A wake or Anaesthetised Human
Subjects. Propranolol reduced heart rate and cardiac output by about 10% to 20070 when administered to conscious resting human subjects. 76 ,77 Arterial blood pressure did not fall because an elevation of SVR compensated for the reduction in cardiac output. Intravenous practolol has been shown 78 to reduce heart rate while sparing cardiac output, SVR and MAP. The difference in effect between the two drugs is probably responsible for the observation that practolol was less likely to precipitate Anaesthesia and Intensive Care, Vol. VIII, ·No. 3, August, 1980 circulatory failure when these drugs were used in the treatment of supraventricular cardiac arrhythmias. 79 During anaesthesia the observed effects of beta-blockade in humans are consistent with those observed in the dog under similar conditions. Intravenous propranolol has been widely employed in the control of ventricular arrhythmias during anaesthesia. 80, 81, 82, 83, 84 Practolol has proved equally effective in this respect. 85, 86, 39 Hypertensive patients subjected to laryngoscopy prior to endotracheal intubation showed alarming elevations in blood pressure often accompanied by ventricular ectopic beats and unmistakable ECG evidence of severe myocardial ischaemia. Practolol has been shown 45 to protect against these undesirable and possibly dangerous abnormalities of cardiovascular function. All other beta-blockers have a similar protective effect.
These successful applications of beta blockade during anaesthesia prompted intensive studies of the systemic and coronary haemodynamic consequences of acute betablockade. 10rfeldt and colleagues 34 studied the effects of 5 mg propranolol or 2.5 mg alprenolol intravenously in normal patients during 1.5% halothane anaesthesia with IPPV. When the drugs were given during anaesthesia and before operation only minor effects on heart rate, cardiac output, SVR and mean arterial pressure were observed. If the drug was given during surgery, heart rate fell in many patients and this reduction was accompanied by a fall in cardiac output. Intravenous atropine restored heart rate and cardiac output to control levels. It was inferred that vagal activity was higher during surgery than before surgery, and similar findings have been reported by other investigators. 82 ,87,39,85 All these authors have emphasised the necessity for enough atropine to be given in order to reduce the effect of unopposed parasympathetic activity on the heart during anaesthesia in the presence of beta blockade. The reason for the depression of cardiac performance by relative vagal overactivity is not completely clear. It is most likely to be due solely to an inability of the heart to increase stroke volume at slow heart rates and so maintain cardiac output. A direct depressant effect of vagal activity on myocardial contractility has been reported~~ but is regarded to be of no significance in vivo.
The Effects of Beta-Blockers on the Coronary Circulation. The effects of beta blockade on the coronary circulation have been studied in animal preparations. Whitsitt and Lucchesi 89 studied conscious dogs and found that propranolol had no effect on coronary blood flow (CBF), myocardial oxygen consumption (MVO z ) or the efficiency of the myocardium expressed as the ratio of external left ventricular work on MV0 2 • Nayler et al. 90 reported that, in a dog heart lung preparation, propranolol reduced CBF and MVO z and that these changes were associated with a reduction in myocardial contractility. Pitt et af.9 1 ,92 concluded that even though there was evidence that in certain circumstances beta-receptors mediate a degree of vasodilatation in the coronary vasculature of conscious dogs, the receptors appeared to be of little physiological significance and their activity was certainly not essential to life.
Nayler and Chang 55 showed that propranolol 0.5 mg/kg, practolol 2.0 mg/kg or oxprenolol 0.5 mg/kg, greatly improved tJ1e ratio between left ventricular work and MV0 2 (myocardial efficiency) in the dog. The deterioration in this ratio observed in the intact animal during electrical stimulation of the stellate ganglion was totally prevented by beta-blockade. During light halothane anaesthesia in dogs, Merin and Tonnesen 64 found that propranolol 0.25 mg/kg did not alter myocardial oxygen consumption or blood flow despite a fall in left ventricular stroke work and cardiac output. In similar experiments, practolol 1.2 mg/kg increased stroke work, myocardial blood flow and oxygen consumption to a comparable extent and no change was observed in the stroke work/ oxygen uptake ratio. 66 Bussman et al. 93 reported increased coronary blood flow after practolol with no change in MVO,. This effect was attributed to an active coron'ary vasodilatation mediated by the action of ISA on beta-2 receptors in the coronary arteries. No change in myocardial efficiency after propranolol could be demonstrated by McKenna et al. 94 or Whitsitt and Lucchesi. 89 Using an open chest canine model, Burt and Foex 95 found that the cardioselective drug metoprolol (which lacks ISA) in a dose of 1.0 mg/kg during halothane anaesthesia decreased cardiac output by 21!1Jo and myocardial oxygen requirement was reduced proportionately. They concluded that while such a reduction in cardiac output during halothane anaesthesia may clinically be unacceptable, the increase in myocardial oxygen consumption caused by practolol (+ ISA) under similar conditions 66 could be dangerous if coronary blood flow was compromised by coronary vascular disease.
The evidence from different studies relating to the effect of beta-blockade on myocardial efficiency is therefore not always consistent and this may be due to variations in experimental preparations and techniques. 96 On balance, however, it appears that blockade of cardiac beta-receptors may either have a beneficial effect on cardiac efficiency or at worst have no effect at all. There is no evidence that cardiac beta-adrenergic blockade decreases the mechanical efficiency of the heart either in the awake or anaesthetised state. Opinion is sharply divided, however, on the possible consequences of long term betablocker therapy being continued into the immediate preoperative period. The difficulties of assessing the possible interactions of this form of therapy with anaesthesia are many. It would be difficult to conduct a controlled "within patient" clinical trial and indeed none have been reported. The patients who present for surgery while taking beta-blockers are often suffering from a cardiovascular disease which in itself increases the risks of anaesthesia and surgery, and the same operation may be more or less traumatic in different patients. In view of these factors it is not surprising that anaesthetists hold conflicting views on the safety of anaesthesia during long term treatment with beta-blockers.
Several authors have published balanced assessments of the problem. The consensus of these authors is that if beta-blockers are recognised as potent agents and their pharmacology, as well as that of anaesthetic drugs to be used, is taken into account, anaesthesia during long term therapy with betablockers should not represent a major hazard. 96 ,97,98,99,100,101 These publications review the contraindications and dangers of betablockers and consider that any decision to suspend therapy before operation must be related to the patient concerned. The potential dangers of withdrawal of the drugs must also be considered. 48 ,53 These include "rebound" hypertension, exacerbation of angina and an increased incidence of myocardial infarction.
The view that beta-blockade represents a major hazard during anaesthesia is taken by other authors, but several reports are unsubstantiated by sound evidence. Ayscue lO2 stated that a fatal outcome often ensued when patients suffering from coronary artery disease (CAD) and treated with propranolol were anaesthetised with volatile agents. He considered that in these circumstances, gross cardiac depression, unresponsive to atropine or isoprenaline, could occur during the course of anaesthesia. ShimosatolO 3 expressed similar views and stated that cardiac depression due to propranolol may last "several weeks" after the cessation of therapy. Fabian lO4 advised that propranolol treatment be ceased 24 to 48 hours pre-operatively in patients with CAD in order to reduce the anaesthetic risk. Prys-Roberts l4 found that a group of renal hypertensive patients being treated with very high doses of a variety of beta-blockers tolerated surgery for renal revascularisation well. A nitrous oxide/ oxygen/narcotic analgesic/relaxant technique was employed and the only potentially deleterious effect observed was an atropine resistant bradycardia after neostigmine administration. In studies of patients undergoing cardiac surgery, Viljoen and Gindi lO5 and Viljoen et al. 51 considered that the continuation of propranolol therapy into the immediate pre-operative period resulted in the failure of several patients to regain satisfactory cardiac function after cardiopulmonary bypass for coronary artery surgery. These authors also observed low cardiac output states refractory to sympathomimetic agents and attributed this condition to the effect of beta-blockers. This effect has not been observed by other anaesthetists who deal with cardiac surgery. H16, 107
Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 The opinions of Katz and Bigger lO8 are typical of those of many anaesthetists. These authors considered that beta blockade may impair the ability of patients to compensate for blood loss, hypotension induced by anaesthetic agents, or for hypoxia but they did not substantiate their views. The animal experiments previously referred to were designed to clarify the effects of acute and long term beta blockade on cardiovascular responses to clinical anaesthesia, and to haemorrhage and hypoxia occurring during anaesthesia. Only in this way could fact be separated from speculation and the nature of some of the interactions be defined. While certain definite adverse interactions have been elucidated not every possible combination of different beta-blockers and anaesthetic agents or techniques has been systematically studied. Newer drugs such as labetolol which have other actions apart from beta-blockade, in this case an alpha-blocking action, must be treated with caution although labetolol has been used successfully to achieve induced hypotension in healthy young patients during nitrous oxide/oxygen halothane anaesthesia with dTc and IPpV. I 09 CONCLUSIONS Beta-blockers are in common use for a number of clinical indications -the most common, and therefore most relevant to the anaesthetist, being symptomatic ischaemic heart disease and arterial hypertension. The following major considerations apply to the conduct of anaesthesia and the general management of the patient during the peri-and intra-operative periods.
Despite some pharmacological differences between individual beta-blocking drugs they have similar interactions with anaesthetic agents and techniques. Long term treatment with beta-blockers, in the author's view, should be continued up to and including the day of surgery. If withdrawal of therapy or reduction in dosage be considered necessary this should be gradual and the patient should be observed in hospital during this period.
The anaesthetic agent(s) and technique should be appropriate to the needs of the individual patient. It appears that cyclopropane, diethyl ether, fluroxene, trichlorethylene, methoxyflurane and possibly enflurane should not be used in a beta-blocked patient. Provided that carbon dioxide retention is avoided, halothane, isoflurane, nitrous oxide, the available intravenous induction agents, muscle relaxants, narcotic analgesics and local anaesthetics are all compatible with beta-adrenergic blockade. The use of local anaesthetic agents combined with vasoconstrictors should be approached with caution. Systemic absorption of the vasoconstrictor, usually adrenaline, occurs and can result under these conditions to an unopposed alpha-stimulation causing increased peripheral resistance, increased impedance to left ventricular ejection and strain on the myocardium.
During anaesthesia and surgery, accidental hypovolaemia or hypoxia may occur due to misjudgement, technical error or equipment failure. Despite some contrary opinion it would appear that beta-blocked patients negotiate these perils as well as untreated patients because the sympathetic stress response is markedly obtunded even in the untreated patient if adequate anaesthesia has been provided. This is self-evident as the object of anaesthesia is to ablate consciousness, provide optimal surgical conditions and to minimise unwanted reflex activity. Despite this, meticulous attention should be paid to oxygenation and the maintenance of blood volume in beta-blocked patients. If bradycardia reduces cardiac output and blood pressure, atropine administration usually suffices. It is unusual for a beta-agonist to be necessary but if such a drug is used it should be given intravenously in small doses titrated against the patient's response. The drug of choice is isoprenaline as this agent is a virtually pure beta-agonist.
In view of the reports of atropine resistant bradycardia after neostigmine administration it is wise to avoid neostigmine in patients who have been receiving very high doses of betablockers (e.g. for renal hypertension). IPPV can be continued post-operatively until the effects of non-depolarising muscle relaxants have worn off.
The post-operative period must not be neglected. Often the indication for betablockade exists just as strongly at this time as before or during operation. Post-operative pain and apprehension may trigger potentially harmful increases in heart rate or blood pressure. Oral beta-blocker therapy should be reinstituted as soon as possible. If the oral route of administration is contraindicated, an intravenous regime, titrated according to response, should be instituted. In the latter case doses much smaller than would be used orally should be given as there is no hepatic "first pass" effect. Continuous infusion is preferable to intermittent bolus injection.
Postoperatively all staff caring for the patient must be aware that heart rate is relatively fixed and not an indicator of possible blood loss and requirement for transfusion. Blood pressure, state of cerebration, peripheral perfusion and urine output should be used to detect the presence of occult haemorrhage.
